User:Delphinewiki/sandbox

BertinPharma is the life sciences subsidiary of Bertin Technologies, department of CNIM company , created in 1991. It employs over 100 scientific people in France. Its turnover for 2013 amounts 12 millions euros. Bertin Pharma offers CRO services along with Bioreagent tools, in the fields of pharmacology, biotechnologies, cosmetics and nutrition for both industries and academic research.

• 1989 : Inception of Biotec Centre
Biotec Centre was launched in 1989 in Orleans (France) by Norbert and Maguy Bromet. Biotec Centre is specialized in clinical studies, pharmacokinetics, metabolism, and bioanalysis services. Biotec Centre favours automated blood sampling using a robot called Culex. This instruments allows to work on very small blood sampling in non-stress conditions. Biotec Centre is the first CRO in Europe to use this method.



• 1991 : Inception of SPI-Bio
SPI-Bio company is a spin-off of the French public research organization : French Atomic Energy and Alternative Energies Commission (CEA- Life Sciences divison). Launched in 1991 to facilitate the development and  the standardization of CEA innovations, Spi-Bio develops, manufactures and markets EIA for xenobiotics and biomarkers.



• 1999 : Creation of Ellipse Pharmaceuticals and IDPS
Bertin Technologies (previously Bertin & Cie) is a French company specialized in prototypes manufacturing and technology consulting in the fields of aeronautic, defence, transport and energy. In 1999, Bertin Technologies decided to expand its sectoral scope toHealth and Environment fields, creating the company Ellipse Pharmaceutical in 1999 in Pessac near Bordeaux (France).

The Institut Développement Produits Santé(IDPS) is a pharmaceutical company, founded by Marie and François Mourgues in 1999.

• 2004 : Bertin Technologies acquires Spi-Bio
Bertin Technologies reinforced its Life Sciences Division when it acquired SPI-Bio in 2004 as Health represents now one-third of its activities.

• 2008 : SPI-Bio acquires Biotec Centre
SPI-Bio acquired Biotec Centre and places Bertin Technologies as the leader of Life Sciences market in  France.

• 2009 : SPI-Bio acquires IDPS
On August 31st 2009, nine months after acquiring Biotec Centre, Spi-Bio acquired IDPS and fell within Bertin  Technologies growing fast  strategy.



• 2010 : Creation of Bertin Pharma
On July 1st 2010, Bertin Pharma was born as a result of the merging of the four subsidiaries : Biotec Centre, SPI-Bio, Ellipse Pharmaceuticals and IDPS. The structure of the organization is simplified and brings together many skills : pharmaceutical development and bioanalysis platforms during non-clinical and clinical drug development phases, support to pharmacology, pharmacokinetic studies. Bertin Pharma also provides reagents  and assay kits for bioanalysis.

• 2011 : Bertin Pharma certified by the AFSSAPS
Since the inspection of the AFFSAPS (French Agency for the Safety of Health Products) in 2011, Bertin Pharma is fully certified (A) conform to the GLP (Good Laboratory Practice).

• July 2011 : Bertin Pharma is opening its new premises
On July 1st 2011, Bertin Pharma brought its teams of  Pressac and Artigues together in a unique place : the previous IDPS site in Artigues-Près-Bordeaux. Bertin Pharma inaugurated the refurbished and extended premises in the presence of Nicolas Dmitrieff, President of CNIM Group and Philippe Demigné, President of  Bertin.

With 2 million euros of investment, the place covers 2000sqm GMP certified, and houses 50 people.

For many years, Bertin Pharma collaborates with different players of drug development in this area such as : the Institut de Pharmacie de Bordeaux, Paul Pascal Research Center, the ITERG and also the Institut de la Garonne sur Agen.

• 2012 : Bertin Pharma Received the CRO Leadership Awards
In 2012, Bertin Pharma received a Productivity award from Nice Insight, marketing company, and the Life Sciences Leader magazine.

• January 2014 : Bertin Pharma acquires Johnson & Johnson site
Bertin Pharma acquired Johnson & Johnson Santé Beauté R&D (JJSBF) site in Martillac (France). This R&D facility of 1500sqm is dedicated to the formulation of OTC drugs (over-the-counter) clinical batches.

In addition to this acquisition, a partnership agreement has been signed and  Bertin Pharma will provide R&D services to JJSBF. Bertin Pharma is now entering the self-treatment growing market.

• April 2014 : FDA approved
The Food and Drug Administration (FDA) is an agency within the United States Department of Health and Human Services. Amongst other missions, the FDA have the mandate to authorize drugs to be marketed in United States territory.

In April 2014, the FDA inspected Bertin Pharma's premises in Artigues (France) and approved their compliance to the Good Manufacturing Practices (GMP) as Bertin Pharma flawlessly passed the inspection. Since the company is able to collaborate with international partners.

Activities
Bertin Pharma is a CRO, Bioreagent and Bioanalysis provider.

• CRO : Contract Research Organization
As a Contract Research Organization, Bertin Pharma assists customers during the value chain of drug development :

- Translational medicine - Medical devices - Clinical studies - Non clinical studies - Biomarkers - Pharmaceutical development

• Bioreagent and Bioanalysis provider
As a bioreagent and bioanalyis provider, Bertin Pharma develops and distributes ranges of laboratory consumables :

- Pre-analytical products - Assays - Polyclonal & monoclonal antibodies - Chemicals - Cloning & gene expression - Tag protein purification - Transfection - Proteins - Cell surface marker

Bertin Pharma distributes these products through international providers and brands including :

- Cayman Chemical - SPI-bio - IBA - MS2Plex

• Medicen
Bertin Pharma is one of the board members of Medicen.

Founded in 2005, the Medicen Paris Region competitiveness cluster “aims to position the Paris Region as a European industrial leader in diagnostic and therapeutic innovation and leading-edge health technologies, thus enabling it to become one of the global centres for translational medicine.”

• AFSSI
Bertin Pharma is one of the 13 founding members of the AFSSI, French Association of Outsourcing and Innovative Companies in the field of Life Sciences.ref>

Founded in 2012, this French association represents both large and small companies investing “a significant part of their revenues in R&D to update and broaden their technology offering in order to run research programs on behalf of  third parties.” ref>

Philippe GENNE, President and CEO of the company Oncodesign is the president of the AFSSI. Xavier Morge, Director General of Bertin Pharma is, as for him, the Vice-President of the AFSSI. ref>

• IDMIT CENTER
Bertin Pharma, along with The Life Sciences Division of the CEA, the Institut Pasteur, the  Institut National de la Santé et de la Recherche Médicale (INSERM), the Agence Nationale de Recherche sur le  SIDA et les Hépatites Virales (ANRS) and the Université Paris Sud 11(UPS-11), created the Infectious Disease Models and Innovative Therapies center (IDMIT Center).ref>

Located at the CEA site in Fontenay-aux-Roses, this center is dedicated to preclinical research programs on human vaccines and antimicrobial treatments.ref>

Locations
Bertin Pharma is located on 4 sites in France : Montigny-le-Bretonneux(headoffice),Orléans, Martillac and Artigues-près-Bordeaux.ref>